24 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee. Read more…
Significant milestones reached, well capitalised and positioned for future growth London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022. Read more…
Key highlights · Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia · Allows for use in combination with an antiviral agent · Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline 8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that […]
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indication · Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]
Early data read out indicates a successful LPS human challenge trial Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full […]
